Methods for the detection and diagnosis of endometriosis are disclosed herein. More specifically, sensitive single-cell expression analysis methods to detect specific gene expression patterns in cell populations obtained from endometrial cells are provided.

Disclosed herein are compositions and methods useful for the diagnosis, assessment, and characterization of endometriosis in a subject in need thereof, based upon the expression level of at least one miRNA that is associated with endometriosis.

The presence of certain auto antibodies and miRNAs indicates that a subject has endometriosis. The auto-antibodies recognise antigens listed in Table 1. The miRNAs are also listed in Table 1.

Provided is a method of non-invasively diagnosing endometriosis in a subject comprising maintaining or culturing stromal cells, obtained from a menstrual effluent or discharge sample from the subject. Also provided is a method of non-invasively diagnosing fertility in a subject. Also provided is a kit for non-invasively diagnosing endometriosis in a subject. Also provided is a method of treating endometriosis in a subject. Also provided is a method of preventing the progression or development of endometriosis in a subject.

Disclosed herein are compositions and methods useful for the diagnosis, assessment, and characterization of endometriosis in a subject in need thereof, based upon the expression level of at least one miRNA that is associated with endometriosis.

A method of detecting the expression level of miRNA markers in a biological sample obtained from a mammal is provided. The method incudes the steps of i) detecting the expression level of one or more miRNA markers selected from the group of miR-199a-3p, miR-143-3p, miR-340-5p, let-7b-5p, miR-21-5p, miR-17-5p, miR-20a-5p and miR-103a-3p, in the biological sample; ii) detecting the expression level of at least one miRNA reference marker selected from miR-148b-3p and miR-30e-5p in the biological sample; and iii) normalizing the expression level of the miRNA marker(s) against the expression level of the miRNA reference marker in the sample and in a control. The method is useful for the diagnosis of endometriosis, monitoring of patient response to treatment, and assessment of disease progression and/or severity.

Provided herein are methods of determining whether a subject is afflicted with an endometriosis-related condition, such as endometriosis. Also provided herein are therapies for endometriosis-related conditions.

A method is provided for determining antioxidant power of a sample of a biological fluid or a food. The method essentially consists in contacting the sample to be tested with an aqueous solution of platinum nanoparticles, an oxidizing agent, and a chromogenic peroxidase substrate, and detecting color of the final solution thus obtained. Color intensity of the solution is proportional to the antioxidant power of the sample. A kit suitable for carrying out the method is also provided.

Disclosed are methods of diagnosing and treating endometriosis, and in particular, endometriosis-associated infertility.

The invention relates to a method for determining the presence of a tissue injury and repair (TIAR) process in the uterus of a subject. The presence of TIAR is employed as a marker for the presence of a preliminary stage and/or increased risk of developing a medical disorder associated with abnormal formation of endometrial tissue. Such medical conditions are preferably an archimetrosis, such as endometriosis or adenomyosis. The method comprises determining a level of CXCL12 and/or CXCR4 in a sample from a subject.